Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting

December 12, 2022

https://www.globenewswire.com/news-release/2022/12/12/2572217/0/en/Neoleukin-Therapeutics-Presents-Preclinical-Data-on-NEO-TRA1-at-American-Society-of-Hematology-ASH-Annual-Meeting.html

SEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data on NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits that is targeted to and selectively expands inhibitory T-regulatory cells. The data are being disclosed today as an oral presentation at the American Society of Hematology (ASH) Annual Meeting.

Read more at globenewswire.com

Related news for (NLTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.